Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
Total Valuation
NovoCure has a market cap or net worth of $1.37B. The enterprise value is $1.55B.
Market Cap$1.37B
Enterprise Value$1.55B
Share Statistics
NovoCure has 113,794,395 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding113,794,395
Owned by Insiders2.19%
Owned by Institutions12.47%
Financial Efficiency
NovoCure’s return on equity (ROE) is -0.40 and return on invested capital (ROIC) is -25.94%.
Return on Equity (ROE)-0.40
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-25.94%
Return on Capital Employed (ROCE)-0.26
Revenue Per Employee440.43K
Profits Per Employee-91.55K
Employee Count1,488
Asset Turnover0.81
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NovoCure is ―. NovoCure’s PEG ratio is 0.49.
PE Ratio―
PS Ratio2.20
PB Ratio4.23
Price to Fair Value4.23
Price to FCF-19.05
Price to Operating Cash Flow-27.30
PEG Ratio0.49
Income Statement
In the last 12 months, NovoCure had revenue of 655.35M and earned -136.23M in profits. Earnings per share was -1.22.
Revenue655.35M
Gross Profit488.47M
Operating Income-153.80M
Pretax Income-136.25M
Net Income-136.23M
EBITDA-119.05M
Earnings Per Share (EPS)-1.22
Cash Flow
In the last 12 months, operating cash flow was -49.03M and capital expenditures -26.65M, giving a free cash flow of -75.68M billion.
Operating Cash Flow-49.03M
Free Cash Flow-75.68M
Free Cash Flow per Share-0.67
Dividends & Yields
NovoCure pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.40
52-Week Price Change-40.13%
50-Day Moving Average12.73
200-Day Moving Average13.55
Relative Strength Index (RSI)45.51
Average Volume (3m)2.64M
Important Dates
NovoCure upcoming earnings date is Apr 23, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateApr 23, 2026
Ex-Dividend Date―
Financial Position
NovoCure as a current ratio of 2.90, with Debt / Equity ratio of 85.18%
Current Ratio2.90
Quick Ratio2.90
Debt to Market Cap0.17
Net Debt to EBITDA-1.57
Interest Coverage Ratio0.00
Taxes
In the past 12 months, NovoCure has paid -23.00K in taxes.
Income Tax-23.00K
Effective Tax Rate<0.01
Enterprise Valuation
NovoCure EV to EBITDA ratio is -13.67, with an EV/FCF ratio of -21.51.
EV to Sales2.48
EV to EBITDA-13.67
EV to Free Cash Flow-21.51
EV to Operating Cash Flow-33.20
Balance Sheet
NovoCure has $457.52M in cash and marketable securities with $290.00M in debt, giving a net cash position of $167.52M billion.
Cash & Marketable Securities$457.52M
Total Debt$290.00M
Net Cash$167.52M
Net Cash Per Share$1.47
Tangible Book Value Per Share$3.05
Margins
Gross margin is 74.54%, with operating margin of -23.47%, and net profit margin of -20.79%.
Gross Margin74.54%
Operating Margin-23.47%
Pretax Margin-20.79%
Net Profit Margin-20.79%
EBITDA Margin-18.17%
EBIT Margin-20.79%
Analyst Forecast
The average price target for NovoCure is $25.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$25.50
Price Target Upside112.32% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast11.17%
EPS Growth Forecast-15.64%